| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro SM Graham, HG Jørgensen, E Allan, C Pearson, MJ Alcorn, L Richmond, ... Blood, The Journal of the American Society of Hematology 99 (1), 319-325, 2002 | 1504 | 2002 |
| Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells HG Jørgensen, EK Allan, NE Jordanides, JC Mountford, TL Holyoake Blood 109 (9), 4016-4019, 2007 | 394 | 2007 |
| JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo P Gallipoli, A Cook, S Rhodes, L Hopcroft, H Wheadon, AD Whetton, ... Blood, The Journal of the American Society of Hematology 124 (9), 1492-1501, 2014 | 161 | 2014 |
| Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters A Davies, NE Jordanides, A Giannoudis, CM Lucas, S Hatziieremia, ... Leukemia 23 (11), 1999-2006, 2009 | 125 | 2009 |
| Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate HG Jørgensen, M Copland, EK Allan, X Jiang, A Eaves, C Eaves, ... Clinical cancer research 12 (2), 626-633, 2006 | 122 | 2006 |
| Characterization of cancer stem cells in chronic myeloid leukaemia HG Jørgensen, TL Holyoake Biochemical Society Transactions 35 (5), 1347-1351, 2007 | 121 | 2007 |
| Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells B Zhang, S Chu, P Agarwal, VL Campbell, L Hopcroft, HG Jørgensen, ... Blood, The Journal of the American Society of Hematology 128 (23), 2671-2682, 2016 | 118 | 2016 |
| α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571 HG Jørgensen, MA Elliott, EK Allan, CE Carr, TL Holyoake, KD Smith Blood, The Journal of the American Society of Hematology 99 (2), 713-715, 2002 | 107 | 2002 |
| Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation P Gallipoli, F Pellicano, H Morrison, K Laidlaw, EK Allan, R Bhatia, ... Blood, The Journal of the American Society of Hematology 122 (19), 3335-3339, 2013 | 104 | 2013 |
| BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry A Hamilton, L Elrick, S Myssina, M Copland, H Jørgensen, JV Melo, ... Leukemia 20 (6), 1035-1039, 2006 | 104 | 2006 |
| Nano‐curcumin safely prevents streptozotocin‐induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus R Ganugula, M Arora, P Jaisamut, R Wiwattanapatapee, HG Jørgensen, ... British journal of pharmacology 174 (13), 2074-2084, 2017 | 98 | 2017 |
| Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells EK Allan, TL Holyoake, AR Craig, HG Jørgensen Leukemia 25 (6), 985-994, 2011 | 98 | 2011 |
| Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence S Darici, H Alkhaldi, G Horne, HG Jørgensen, S Marmiroli, X Huang Journal of Clinical Medicine 9 (9), 2934, 2020 | 92 | 2020 |
| Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro HG Jørgensen, EK Allan, SM Graham, JL Godden, L Richmond, MA Elliott, ... Leukemia 19 (7), 1184-1191, 2005 | 89 | 2005 |
| CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression A Tarafdar, LEM Hopcroft, P Gallipoli, F Pellicano, J Cassels, A Hair, ... Blood, The Journal of the American Society of Hematology 129 (2), 199-208, 2017 | 77 | 2017 |
| The emerging role of H3K9me3 as a potential therapeutic target in acute myeloid leukemia L Monaghan, ME Massett, RP Bunschoten, A Hoose, PA Pirvan, ... Frontiers in oncology 9, 705, 2019 | 63 | 2019 |
| Neutralisation of TGFβ or binding of VLA-4 to fibronectin prevents rat tendon adhesion following transection HG Jørgensen, SD McLellan, JF Crossan, ASG Curtis Cytokine 30 (4), 195-202, 2005 | 55 | 2005 |
| Evolving molecular therapy for chronic myeloid leukaemia—are we on target? M Copland, HG Jørgensen, TL Holyoake Hematology 10 (5), 349-359, 2005 | 50 | 2005 |
| Binding of imatinib by α1-acid glycoprotein C Gambacorti-Passerini, P le Coutre, M Zucchetti, M D'Incalci Blood, The Journal of the American Society of Hematology 100 (1), 367-369, 2002 | 48 | 2002 |
| Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib S Hatziieremia, NE Jordanides, TL Holyoake, JC Mountford, ... Experimental hematology 37 (6), 692-700, 2009 | 46 | 2009 |
Tessa L HolyoakeProfessor of Experimental Haematology, Institute of Cancer Sciences, University of GlasgowVerified email at glasgow.ac.uk
